HK1249737A1 - 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 - Google Patents

布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 Download PDF

Info

Publication number
HK1249737A1
HK1249737A1 HK18109251.5A HK18109251A HK1249737A1 HK 1249737 A1 HK1249737 A1 HK 1249737A1 HK 18109251 A HK18109251 A HK 18109251A HK 1249737 A1 HK1249737 A1 HK 1249737A1
Authority
HK
Hong Kong
Prior art keywords
bruton
tyrosine kinase
solvates
conditions
kinase inhibitor
Prior art date
Application number
HK18109251.5A
Other languages
English (en)
Chinese (zh)
Inventor
Erick Goldman
Mark Stephen Smyth
Thierry Bonnaud
Alberto MUNOZ GARCIA
Christopher Peter Worrall
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of HK1249737A1 publication Critical patent/HK1249737A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18109251.5A 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 HK1249737A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139594P 2015-03-27 2015-03-27
US201562139594P 2015-03-27
PCT/US2016/024305 WO2016160598A1 (en) 2015-03-27 2016-03-25 Solvated forms of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
HK1249737A1 true HK1249737A1 (zh) 2018-11-09

Family

ID=57006292

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18109251.5A HK1249737A1 (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
HK18107889.9A HK1248147A1 (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18107889.9A HK1248147A1 (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式

Country Status (11)

Country Link
US (4) US20180072738A1 (enExample)
EP (1) EP3273961A4 (enExample)
JP (2) JP2018509457A (enExample)
CN (1) CN107530346A (enExample)
AU (1) AU2016243116A1 (enExample)
BR (1) BR112017020744A2 (enExample)
CA (1) CA2981048A1 (enExample)
HK (2) HK1249737A1 (enExample)
MA (1) MA41827A (enExample)
MX (1) MX2017012430A (enExample)
WO (1) WO2016160598A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US11001585B2 (en) 2015-08-19 2021-05-11 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
CZ2016276A3 (cs) * 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
MX2022003340A (es) * 2019-09-18 2022-06-14 Prelude Therapeutics Inc Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
CN114478547A (zh) * 2020-10-23 2022-05-13 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3303707A1 (de) * 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
CO5210907A1 (es) * 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) * 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
AU2014251028A1 (en) * 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
CN106008516A (zh) * 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
US20190367519A1 (en) 2019-12-05
AU2016243116A1 (en) 2017-10-19
JP2022033783A (ja) 2022-03-02
EP3273961A4 (en) 2018-10-31
HK1248147A1 (zh) 2018-10-12
WO2016160598A1 (en) 2016-10-06
US20180072738A1 (en) 2018-03-15
CA2981048A1 (en) 2016-10-06
US20200347063A1 (en) 2020-11-05
BR112017020744A2 (pt) 2018-07-17
CN107530346A (zh) 2018-01-02
JP2018509457A (ja) 2018-04-05
MX2017012430A (es) 2018-07-06
MA41827A (fr) 2018-01-30
US20220106317A1 (en) 2022-04-07
EP3273961A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
ZA202502152B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
HK1249736A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的共结晶体
HK1249737A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
EP4338738A3 (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
PH12020552065A1 (en) Ibrutinib combination therapy
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2018033853A3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
HK1224173A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
HK1206726A1 (en) Imidazotriazinone compounds
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
MX383514B (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
MA41643B1 (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
MX2016011674A (es) Combinacion que comprende un inhibidor de btk y un inhibidor de akt.
HK1228260A1 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy